Eurofins BioPharma Product Testing Columbia supports Plus Therapeutics’ Key RNLTM Development and cGMP Drug Manufacturing
COLUMBIA, Missouri, May 12, 2021 – Eurofins BioPharma Product Testing Columbia (the “Company”), part of the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide, today announced a collaboration agreement with Plus Therapeutics, Inc. (“Plus Therapeutics”), a clinical stage pharmaceutical company developing novel, targeted therapies for rare and difficult cancers. The Company will support Plus Therapeutics’ process development and analytical chemistry activities for the cGMP manufacturing of Rhenium NanoLiposome (RNL™), Plus Therapeutics’ lead investigational asset in clinical development for recurrent glioblastoma.
Under the Company’s agreement with Plus Therapeutics, the Company will develop and validate test methods for purity, composition, and identity of Re-BMEDA, the active pharmaceutical ingredient (API) in RNL™. These test methods will support release testing and compliance with cGMP requirements for new drug substances.
“Process optimization and appropriate quality controls of investigational compounds are very critical aspects in bringing novel drugs to markets,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “We have identified a best-in-class partner in Eurofins to help us get one step further in bringing RNL to a registrational clinical trial and ultimately commercial supply.”
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.
